Benzinga | Sep 15, 2021 07:32AM EDT

BridgeBio Pharma Receives FDA Fast Track Designation For Investigational Therapy For The Treatment Of Limb-girdle Muscular Dystrophy Type 2i

BridgeBio Pharma, Inc. (NASDAQ:BBIO),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that the United States Food and Drug Administration (FDA) granted Fast Track designation for the investigation of BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i). The FDA grants development programs Fast Track designation to help drive the development and expedite its review process for drugs being investigated to treat serious conditions and fill unmet medical needs. The FDA utilizes this program to provide patients access to important new drugs as early as possible. This is the fifth Fast Track designation for an investigational therapy that BridgeBio has received this year.